Effects of complement C3/C3b inhibition on control of malignant effusions and neutrophil phenotypes in patients with recurrent epithelial ovarian cancer: Interim analysis of a phase 2 clinical trial
Malignant effusions (ME) can promote metastatic seeding and are challenging to manage. Using ME from patients with epithelial ovarian cancer (OC) and other solid tumors as authentic components of the tumor microenvironment (TME), we observed that ME reprogram neutrophils to acquire complement-depend...
Gespeichert in:
| Veröffentlicht in: | Immunobiology (1979) Jg. 230; H. 4; S. 152995 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Elsevier GmbH
01.07.2025
|
| ISSN: | 0171-2985 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Malignant effusions (ME) can promote metastatic seeding and are challenging to manage. Using ME from patients with epithelial ovarian cancer (OC) and other solid tumors as authentic components of the tumor microenvironment (TME), we observed that ME reprogram neutrophils to acquire complement-dependent T cell suppressor function characterized by inhibition of T cell proliferation and cytokine and metabolic responses. Pegcetacoplan (APL-2) is a C3 and C3b inhibitor approved for paroxysmal nocturnal hemoglobinuria; its use in cancer is novel. The rationale for C3/C3b inhibition includes abrogation of neutrophil recruitment and suppressor function in TME, inhibition of neutrophil extracellular traps (NETs), and reduction of vascular leak driving ME accumulation. We designed a phase 2 trial of pegcetacoplan-based therapy in patients with recurrent OC and persistent MEs (NCT04919629).
This trial is conducted at Roswell Park. It includes 2 sequential safety lead-in cohorts: (i) pegcetacoplan alone for 2 weeks followed by addition of pembrolizumab (n = 3), and (ii) pegcetacoplan + pembrolizumab + bevacizumab (n = 3). Subsequent randomized phase cohorts include: (i) bevacizumab (standard of care), (ii) pegcetacoplan + pembrolizumab, and (iii) pegcetacoplan + pembrolizumab + bevacizumab. Primary endpoints are safety and control of ME. Blood, ME, and tumor tissue are collected at baseline and on therapy.
Pegcetacoplan–based regimens were well-tolerated to date. Among nine evaluable patients, the best observed response has been stable disease (SD) in seven, including two patients who have not required therapeutic drainage of MEs for over 40 weeks. Pegcetacoplan had no impact on total white blood cell or absolute neutrophil counts but partially abrogated the capacity of MEs to induce neutrophil suppressor function and significantly reduced serum markers of NETosis.
In this interim analysis, complement C3/C3b inhibition with pegcetacoplan demonstrates a favorable safety profile and a preliminary signal of ME control in recurrent OC. Immunologic studies suggest that the clinical benefit may be associated with diminished neutrophil suppressor function and NET formation. Further enrollment and long-term follow-up will clarify the therapeutic potential of this novel approach.
This work is supported by NIH R01CA267690. Apellis provided pegcetacoplan and Merck provided pembrolizumab in support of the clinical trial. |
|---|---|
| AbstractList | Malignant effusions (ME) can promote metastatic seeding and are challenging to manage. Using ME from patients with epithelial ovarian cancer (OC) and other solid tumors as authentic components of the tumor microenvironment (TME), we observed that ME reprogram neutrophils to acquire complement-dependent T cell suppressor function characterized by inhibition of T cell proliferation and cytokine and metabolic responses. Pegcetacoplan (APL-2) is a C3 and C3b inhibitor approved for paroxysmal nocturnal hemoglobinuria; its use in cancer is novel. The rationale for C3/C3b inhibition includes abrogation of neutrophil recruitment and suppressor function in TME, inhibition of neutrophil extracellular traps (NETs), and reduction of vascular leak driving ME accumulation. We designed a phase 2 trial of pegcetacoplan-based therapy in patients with recurrent OC and persistent MEs (NCT04919629).
This trial is conducted at Roswell Park. It includes 2 sequential safety lead-in cohorts: (i) pegcetacoplan alone for 2 weeks followed by addition of pembrolizumab (n = 3), and (ii) pegcetacoplan + pembrolizumab + bevacizumab (n = 3). Subsequent randomized phase cohorts include: (i) bevacizumab (standard of care), (ii) pegcetacoplan + pembrolizumab, and (iii) pegcetacoplan + pembrolizumab + bevacizumab. Primary endpoints are safety and control of ME. Blood, ME, and tumor tissue are collected at baseline and on therapy.
Pegcetacoplan–based regimens were well-tolerated to date. Among nine evaluable patients, the best observed response has been stable disease (SD) in seven, including two patients who have not required therapeutic drainage of MEs for over 40 weeks. Pegcetacoplan had no impact on total white blood cell or absolute neutrophil counts but partially abrogated the capacity of MEs to induce neutrophil suppressor function and significantly reduced serum markers of NETosis.
In this interim analysis, complement C3/C3b inhibition with pegcetacoplan demonstrates a favorable safety profile and a preliminary signal of ME control in recurrent OC. Immunologic studies suggest that the clinical benefit may be associated with diminished neutrophil suppressor function and NET formation. Further enrollment and long-term follow-up will clarify the therapeutic potential of this novel approach.
This work is supported by NIH R01CA267690. Apellis provided pegcetacoplan and Merck provided pembrolizumab in support of the clinical trial. |
| ArticleNumber | 152995 |
| Author | Mager, Katherine Puzanov, Igor Zsiros, Emese Suzuki, Sora Gaulin, Nicole Hess, Suzanne McLean, Karen DeJohn, Celia Deschatelets, Pascal Frederick, Peter Segal, Brahm Nazmul Khan, A.N.M. Werner, Sarah Kolev, Martin Giridharan, Thejaswini |
| Author_xml | – sequence: 1 givenname: Emese surname: Zsiros fullname: Zsiros, Emese organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 2 givenname: A.N.M. surname: Nazmul Khan fullname: Nazmul Khan, A.N.M. organization: Moffitt Cancer Center, Tampa, USA – sequence: 3 givenname: Thejaswini surname: Giridharan fullname: Giridharan, Thejaswini organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 4 givenname: Sora surname: Suzuki fullname: Suzuki, Sora organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 5 givenname: Celia surname: DeJohn fullname: DeJohn, Celia organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 6 givenname: Suzanne surname: Hess fullname: Hess, Suzanne organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 7 givenname: Katherine surname: Mager fullname: Mager, Katherine organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 8 givenname: Sarah surname: Werner fullname: Werner, Sarah organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 9 givenname: Karen surname: McLean fullname: McLean, Karen organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 10 givenname: Nicole surname: Gaulin fullname: Gaulin, Nicole organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 11 givenname: Peter surname: Frederick fullname: Frederick, Peter organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 12 givenname: Igor surname: Puzanov fullname: Puzanov, Igor organization: Roswell Park Comprehensive Cancer Center, Buffalo, USA – sequence: 13 givenname: Martin surname: Kolev fullname: Kolev, Martin organization: Apelllis Pharmaceuticals, Waltham, USA – sequence: 14 givenname: Pascal surname: Deschatelets fullname: Deschatelets, Pascal organization: Apelllis Pharmaceuticals, Waltham, USA – sequence: 15 givenname: Brahm surname: Segal fullname: Segal, Brahm organization: Moffitt Cancer Center, Tampa, USA |
| BookMark | eNqFkE1u2zAQRrVIgeanJ-iGF7BDUqYlteiiMNIkQIBu2jUxoobxOBIpkHQKX7DnyjhON90EIEAQ-N43w3dRnYUYsKo-K7lUUq2vd0uaeopLLbVZKqO7zpxV51I1aqG71nysLnLeSak63bTn1d8b79GVLKIXLk7ziBOGIjb19abuBYUt9VQoBsHHxVBSHI_RCUZ6DMBJ9H6fOZAFhEEE3HNk3tIo5i2GWA4zZq4RMxTi4iz-UNmKhG6f0nEQzvzGkYBrnyER8BgIDtMXcR8KJpq4F8ZDptcVgWsho9DCjRTIMVYYGq-qDx7GjJ_e7svq94-bX5u7xcPP2_vN94eFU50xC-M9yH6lUToja92sZO3bdmjRtI3uB2gMQOMa0K7vZMM2e61qv1qvG11D37f1ZVWfel2KOSf0duYVIR2skvao3-7sq3571G9P-pn6dqKQV3smTDY7tuFwIDZR7BDpHf7rf_y_3z_h4V36BewMq8I |
| ContentType | Journal Article |
| Copyright | 2025 |
| Copyright_xml | – notice: 2025 |
| DBID | 6I. AAFTH AAYXX CITATION |
| DOI | 10.1016/j.imbio.2025.152995 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| ExternalDocumentID | 10_1016_j_imbio_2025_152995 S0171298525001299 |
| GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 7X7 88E 88I 8AF 8AO 8FE 8FH 8FI 8FJ 8P~ 8R4 8R5 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGSF ABJNI ABMAC ABMZM ABOHT ABUDA ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACGOD ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADKUU ADMUD ADNMO ADUVX ADVLN AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFKRA AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AHMBA AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BES BHPHI BKOJK BLXMC BNPGV BPHCQ BVXVI CAG CCPQU CJTIS COF CS3 DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GROUPED_DOAJ HCIFZ HMCUK HVGLF HZ~ IHE J1W KOM LK8 LUGTX M1P M2P M2Q M41 M7P MO0 N9A O-L O9- O9~ OAUVE OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X Q38 R2- ROL RPZ S0X SDF SDG SES SEW SPCBC SSH SSI SSU SSZ T5F T5J T5K UKHRP UNMZH VH1 X7M Y6R Z5R ZGI ZXP ~G- ~HD 6I. AAFTH AGCQF M~E PUEGO 9DU AAYXX AFFHD CITATION |
| ID | FETCH-LOGICAL-c1955-5ffa0b42e0c50327403f88d8e5872bda75aa7c7a2cb907016b213f466723abb83 |
| ISSN | 0171-2985 |
| IngestDate | Sat Nov 29 07:36:38 EST 2025 Sat Sep 06 17:19:37 EDT 2025 Tue Oct 14 19:25:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1955-5ffa0b42e0c50327403f88d8e5872bda75aa7c7a2cb907016b213f466723abb83 |
| OpenAccessLink | http://dx.doi.org/10.1016/j.imbio.2025.152995 |
| ParticipantIDs | crossref_primary_10_1016_j_imbio_2025_152995 elsevier_sciencedirect_doi_10_1016_j_imbio_2025_152995 elsevier_clinicalkey_doi_10_1016_j_imbio_2025_152995 |
| PublicationCentury | 2000 |
| PublicationDate | July 2025 2025-07-00 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: July 2025 |
| PublicationDecade | 2020 |
| PublicationTitle | Immunobiology (1979) |
| PublicationYear | 2025 |
| Publisher | Elsevier GmbH |
| Publisher_xml | – name: Elsevier GmbH |
| SSID | ssj0019278 |
| Score | 2.428122 |
| Snippet | Malignant effusions (ME) can promote metastatic seeding and are challenging to manage. Using ME from patients with epithelial ovarian cancer (OC) and other... |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | 152995 |
| Title | Effects of complement C3/C3b inhibition on control of malignant effusions and neutrophil phenotypes in patients with recurrent epithelial ovarian cancer: Interim analysis of a phase 2 clinical trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0171298525001299 https://dx.doi.org/10.1016/j.imbio.2025.152995 |
| Volume | 230 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals issn: 0171-2985 databaseCode: DOA dateStart: 20240101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.doaj.org/ omitProxy: false ssIdentifier: ssj0019278 providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection - Elsevier issn: 0171-2985 databaseCode: AIEXJ dateStart: 19950201 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: false ssIdentifier: ssj0019278 providerName: Elsevier – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources issn: 0171-2985 databaseCode: M~E dateStart: 0 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: false ssIdentifier: ssj0019278 providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLXKAIkXxKcYg8kPvJWWxKnjhLepKgzBKqQNaeIlchKHpmrTKl27sQd-Hj-F38G9dhxXDPElIVVRFcV2onsSXx-fey8hz7xcKvADAnjTOCxQMAY4hVmmJ7nMRc7DnGfa0u_EeBydnsbvO51vNhZmMxNVFV1cxMv_amo4B8bG0Nm_MHfbKZyA_2B0OILZ4fhHhh85hYbWi2v-rzvEzAnDIO2W1aRMS-MnVq1SHXfZwSP_hLIY1HisV1ogh6x6pdZwyXJSzrqoB1sgaWvE5yYlaxMfVyNxr1M9qSXGecyQil9sYCkOX5AMsaULUmoGssS6HC4ZioSOYTLtMhenqYuJbDvObzCOpU0ZhdmlYhFv0RgfV2VtFIOjuXIbTmN5OV_Pum8nhuc96I_7R_1Wc1TWZY4Jq02F5omaytU53IDbKLtcm6rex4tabvMjjLda2oa0s4E7r-fp4TaRKvwei025IDsTsGaLqHQ8x5UZxpAd0345h0fu44BYQio2lUJ_SN19jKPgIOBnIuEXXyPXmeAxfn2Pvoza3a6YGY_B3pPNjqV1iFcG-rkHteUVndwht5vlDD0wMLxLOqq6R26aAqef75OvDRjpoqAOjHQYvAAoUgdFCr8GinhpC0XaQpECFKmDInVQhG6ohSJFKNIWitRBkTZQpAaKL2kDRGqBiONKqoFIGbVApBqID8iHV6OT4WGvqRzSy_yY8x4vCumlA6a8jHsBEwMvKKIojxSPBEtzKbiUIhOSZWkMc54fpswPikEYChbINI2Ch2SnWlTqEaFKRKkIuPKg8SDnuQxYFOZ-oFgumV9Eu-S5tUayNAliEqucnCbaeAkaLzHG2yUDa7HEPgrM1gnA69fNwrZZ4xobl_d3DR__a8M9csu9TU_Izlm9Vk_JjWxzVq7qfU1d7WsUfwfmcegc |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+complement+C3%2FC3b+inhibition+on+control+of+malignant+effusions+and+neutrophil+phenotypes+in+patients+with+recurrent+epithelial+ovarian+cancer%3A+Interim+analysis+of+a+phase+2+clinical+trial&rft.jtitle=Immunobiology+%281979%29&rft.au=Zsiros%2C+Emese&rft.au=Nazmul+Khan%2C+A.N.M.&rft.au=Giridharan%2C+Thejaswini&rft.au=Suzuki%2C+Sora&rft.date=2025-07-01&rft.pub=Elsevier+GmbH&rft.issn=0171-2985&rft.volume=230&rft.issue=4&rft_id=info:doi/10.1016%2Fj.imbio.2025.152995&rft.externalDocID=S0171298525001299 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0171-2985&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0171-2985&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0171-2985&client=summon |